More importantly, despite addressing the DM-associated hyperglycemia, some glucose lowering agents used to treat DM are associated with higher rates of adverse cardiovascular outcomes, including insulin (Action to Control Cardiovascular Risk, 2008; McMurray et al., 2014). The gene discussed is INS; the disease is diabetes mellitus.